Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
J HIV Ther
; 8(4): 96-100, 2003 Nov.
Article
em En
| MEDLINE
| ID: mdl-14671507
ABSTRACT
Severe hepatotoxicity develops in 5-10% of people with HIV infection in the first 12 months following initiation of highly-active antiretroviral therapy (HAART), with continuing risk in subsequent years. The major risk factors for severe hepatotoxicity are underlying chronic viral hepatitis, abnormal baseline levels of serum hepatic transaminases, and nevirapine or high-dose ritonavir-containing antiretroviral therapy regimens. The vast majority of severe hepatotoxicity cases are not associated with development of symptoms of acute hepatitis or other adverse hepatic outcomes and resolve within a few months. Antiretroviral therapy should be discontinued in association with grade 4 elevations in serum hepatic transaminase measurements, hyperlactataemia, symptoms of acute hepatitis, or features of drug hypersensitivity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV
/
Inibidores da Protease de HIV
/
Inibidores da Transcriptase Reversa
/
Terapia Antirretroviral de Alta Atividade
/
Doença Hepática Induzida por Substâncias e Drogas
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J HIV Ther
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
/
TERAPEUTICA
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Austrália